We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 07, 2021

Cetuximab Plus Paclitaxel or Paclitaxel Alone for Recurrent or Metastatic HNSCC

Cancer Medicine


Additional Info

Cancer Medicine
Cetuximab Combined With Paclitaxel or Paclitaxel Alone for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Progressing After EXTREME
Cancer Med 2021 May 25;[EPub Ahead of Print], T Chevalier, A Daste, E Saada-Bouzid, et al

Further Reading